Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blepharitis Eye Diseases Eyelid Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Eye Research Foundation, Inc.

Newport Beach, California, 92663, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Active blepharitis with collarettes

Exclusion criteria

Other clinically significant eye disease

Treatment and study plan

Moxidectin 2 MG Oral Tablet

Drug

active medication

Placebo

Drug

placebo pills

Primary outcomes

Collarette count

Time frame: 6 weels

Collarette Count

Sponsors and collaborators

Lead sponsor

Eye Research Foundation, Inc.

Industry

Registry information

Official study title

A Single-center, Investigator-masked, Randomized, Placebo-controlled, Investigator-initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation.

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Jan 27, 2025
Registry last updated: Aug 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed